Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 10,000 shares of the business's stock in a transaction dated Tuesday, June 22nd. The stock was sold at an average price of $74.56, for a total value of $745,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Derek J. Maetzold also recently made the following trade(s):
- On Monday, April 26th, Derek J. Maetzold sold 14,374 shares of Castle Biosciences stock. The stock was sold at an average price of $69.17, for a total value of $994,249.58.
Shares of NASDAQ:CSTL traded up $0.41 during trading on Thursday, hitting $75.09. 46,364 shares of the company's stock traded hands, compared to its average volume of 285,973. The firm has a market cap of $1.88 billion, a P/E ratio of -105.18 and a beta of 0.42. The firm has a 50-day simple moving average of $64.28. Castle Biosciences, Inc. has a 52 week low of $34.72 and a 52 week high of $107.69.
Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Sunday, May 9th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The firm had revenue of $22.81 million for the quarter, compared to analysts' expectations of $16.66 million. Castle Biosciences had a negative return on equity of 4.74% and a negative net margin of 22.24%. The business's quarterly revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 EPS. As a group, equities analysts predict that Castle Biosciences, Inc. will post -0.92 earnings per share for the current fiscal year.
CSTL has been the subject of several analyst reports. Zacks Investment Research upgraded Castle Biosciences from a "sell" rating to a "hold" rating in a research report on Monday, May 10th. Lake Street Capital started coverage on Castle Biosciences in a report on Friday, April 30th. They set a "buy" rating and a $94.00 price objective on the stock. Finally, Robert W. Baird reiterated a "buy" rating and set a $73.00 price objective on shares of Castle Biosciences in a report on Thursday, May 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Castle Biosciences presently has an average rating of "Buy" and a consensus target price of $80.29.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. Arizona State Retirement System bought a new stake in Castle Biosciences in the 4th quarter valued at approximately $230,000. State of Wisconsin Investment Board raised its stake in shares of Castle Biosciences by 12.3% during the 4th quarter. State of Wisconsin Investment Board now owns 16,400 shares of the company's stock worth $1,101,000 after purchasing an additional 1,800 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Castle Biosciences by 2.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 6,945 shares of the company's stock worth $466,000 after purchasing an additional 178 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Castle Biosciences by 8.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 51,231 shares of the company's stock worth $3,440,000 after purchasing an additional 3,945 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Castle Biosciences by 56.7% during the 4th quarter. Swiss National Bank now owns 40,900 shares of the company's stock worth $2,746,000 after purchasing an additional 14,800 shares in the last quarter. Hedge funds and other institutional investors own 84.99% of the company's stock.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.
Featured Story: Bear Market
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Backdoor Roth IRA Conversion and Strategy7 Tech Stocks That Will Avoid Government Regulation
As if investing in the tech sector did not carry enough risk, there’s a new threat to the tech part of your portfolio. There is a growing sense that the United States Congress will seek to regulate some of the largest tech companies.
At this point, it looks like several of the FAANG stocks (Facebook, Amazon, Apple, Netflix, and Alphabet/Google) may be the initial targets. Some regulation, particularly regarding data security and privacy – not to mention censorship - would be welcome. But we all know it’s not likely to stop there.
What will more extreme regulation look like? If the most vocal members of Congress hold sway, some of these companies may get broken up or face utility-like regulation. From an investment standpoint, it just adds uncertainty.
The good news is that the tech sector encompasses many companies that are likely to avoid government regulation. With areas like cybersecurity, support for remote work, and mobile gaming to continue to pick up steam, there are other areas that can help boost your portfolio.
And in this special presentation, we’ll give you seven of our picks for tech stocks that will avoid government regulation.
View the "7 Tech Stocks That Will Avoid Government Regulation"